Article Details

Innovent Biologics, Inc. Announces a Phase 3 Study of Picankibart ( Anti-IL-23p19 Antibody ...

Retrieved on: 2025-05-29 09:08:14

Tags for this article:

Click the tags to see associated articles and topics

Innovent Biologics, Inc. Announces a Phase 3 Study of Picankibart ( Anti-IL-23p19 Antibody .... View article details on hiswai:

Excerpt

... monoclonal antibodies treatment group. The primary endpoint is the proportion of participants achieving a static Physician's Global Assessment ...

Article found on: www.marketscreener.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo